Remote Monitoring of IBD
Study Details
Study Description
Brief Summary
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) with a heterogeneous disease course. Recurrent mucosal inflammation or chronic subclinical inflammation results in damage to the bowel and complications like stenosis, fistula and colorectal cancer. Therefore, tight control of mucosal inflammation is important to prevent complications.
The goal of this multicenter observational cohort study is to determine the best remote monitoring tool for predicting mucosal inflammation in adult patients with inflammatory bowel disease, relative to the gold standard endoscopy.
Participants will be asked to fill out questionnaires regarding disease activity (MIAH, mHI, IBD-control, Manitoba IBD Index, p-HBI/p-SCCAI), perform a FC home test and collect one stool sample for routine laboratory calprotectin measurement, before the start of the bowel preparation for the ileocolonoscopy. During this ileocolonoscopy, endoscopic disease activity will be determined.
.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Prediction of mucosal inflammation in daily clinical practice with PROMs and FC home test [week 0 (i.e. in the week before the colonoscopy)]
- Recalibration of PROMs [week 0 (i.e. in the week before the colonoscopy)]
Recalibrate PROMs with the FC home test to optimise prediction of mucosal inflammation, relative to the gold standard ileocolonoscopy, for use in daily clinical practice
Secondary Outcome Measures
- prediction of mucosal inflammation in strict trial setting with PROMs and FC home test [week 0 (i.e. in the week before the colonoscopy)]
- Agreement between FC home test and routine laboratory tests [week 0-1 (i.e. FC home test in the week before the colonoscopy and the laboratory test at the day of the colonoscopy)]
- Association between clinical (abdominal pain) and histologic disease activity [week 0-1]
- Association between IBD-control and histologic disease activity [week 0-1]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Established diagnosis of CD or UC according to ECCO guidelines
-
CD or UC patients scheduled for an ileocolonoscopy, or UC patients scheduled for an sigmoidoscopy at the endoscopy ward of one of the participating centers (regardless of indication)
-
Aged 18 years or older
-
Smartphone with internet access (for use FC home test)
Exclusion Criteria:
-
Unclassified IBD
-
Ileostomy, colostomy, ileoanal pouch anastomosis or ileorectal anastomosis
-
Isolated upper gastro-intestinal CD, or isolated peri-anal disease
-
Insufficient knowledge of Dutch language
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Jeroen Bosch Hospital | Den Bosch | Netherlands | ||
| 2 | Catharina Hospital Eindhoven | Eindhoven | Netherlands | ||
| 3 | Maastricht University Medical Centre | Maastricht | Netherlands | ||
| 4 | Franciscus Gasthuis&Vlietland | Rotterdam | Netherlands | ||
| 5 | Zuyderland Medical Centre | Sittard | Netherlands |
Sponsors and Collaborators
- Maastricht University Medical Center
- Maastricht University
Investigators
- Principal Investigator: prof. dr. Pierik, Maastricht University Medical Centre
Study Documents (Full-Text)
None provided.More Information
Publications
- Bennebroek Evertsz' F, Hoeks CC, Nieuwkerk PT, Stokkers PC, Ponsioen CY, Bockting CL, Sanderman R, Sprangers MA. Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn's disease activity. J Clin Gastroenterol. 2013 Nov-Dec;47(10):850-6. doi: 10.1097/MCG.0b013e31828b2196.
- Bennebroek Evertsz' F, Nieuwkerk PT, Stokkers PC, Ponsioen CY, Bockting CL, Sanderman R, Sprangers MA. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis. 2013 Dec;7(11):890-900. doi: 10.1016/j.crohns.2012.11.007. Epub 2012 Dec 24.
- Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut. 2014 Jul;63(7):1092-102. doi: 10.1136/gutjnl-2013-305600. Epub 2013 Oct 9.
- Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol. 2009 Jul;104(7):1754-63. doi: 10.1038/ajg.2009.197. Epub 2009 May 19.
- de Jong MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, Romberg-Camps M, Hameeteman W, Bodelier AGL, Romanko I, Lukas M, Winkens B, Markus T, Masclee AAM, van Tubergen A, Jonkers DMAE, Pierik MJ. Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease. J Crohns Colitis. 2019 Apr 26;13(5):555-563. doi: 10.1093/ecco-jcc/jjy196.
- Van Deen WK, van der Meulen-de Jong AE, Parekh NK, Kane E, Zand A, DiNicola CA, Hall L, Inserra EK, Choi JM, Ha CY, Esrailian E, van Oijen MG, Hommes DW. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol. 2016 Dec;14(12):1742-1750.e7. doi: 10.1016/j.cgh.2015.10.035. Epub 2015 Nov 18.
- NL75205.068.20
- NL9313